Glioblastomas are characterized by fast uncontrolled growth leading to hypoxic areas and necrosis. Signalling from EGFR via mammalian target of rapamycin complex 1 (mTORC1) is a major driver of cell growth and proliferation and one of the most commonly altered signalling pathways in glioblastomas. Therefore, epidermal growth factor receptor and mTORC1 signalling are plausible therapeutic targets and clinical trials with inhibitors are in progress. However, we have previously shown that epidermal growth factor receptor and mTORC1 inhibition triggers metabolic changes leading to adverse effects under the conditions of the tumour microenvironment by protecting from hypoxia-induced cell death. We hypothesized that conversely mTORC1 activation sensitizes glioma cells to hypoxia-induced cell death. As a model for mTORC1 activation we used gene suppression of its physiological inhibitor TSC2 (TSC2sh). TSC2sh glioma cells showed increased sensitivity to hypoxia-induced cell death that was accompanied by an earlier ATP depletion and an increase in reactive oxygen species. There was no difference in extracellular glucose consumption but an altered intracellular metabolic profile with an increase of intermediates of the pentose phosphate pathway. Mechanistically, mTORC1 upregulated the first and rate limiting enzyme of the pentose phosphate pathway, G6PD. Furthermore, an increase in oxygen consumption in TSC2sh cells was detected. This appeared to be due to higher transcription rates of genes involved in mitochondrial respiratory function including PPARGC1A and PPARGC1B (also known as PGC-1a and -b). The finding that mTORC1 activation causes an increase in oxygen consumption and renders malignant glioma cells susceptible to hypoxia and nutrient deprivation could help identify glioblastoma patient cohorts more likely to benefit from hypoxia-inducing therapies such as the VEGFA-targeting antibody bevacizumab in future clinical evaluations. Abbreviations: COI = cytochrome c oxidase subunit I; ERR-a = oestrogenic-related receptor-a; 4E-BP1 = eukaryotic translation initiation factor 4E binding protein 1; MT-CO = mitochondrially encoded cytochrome c oxidase subunit; mTORC1 = mammalian target of rapamycin complex 1; PGC = peroxisome proliferator-activated receptor gamma coactivator; S6K1 = ribosomal S6 kinase 1; S6RP = S6 ribosomal protein; SEGA = subependymal giant cell astrocytoma
Introduction
Glioblastoma is an incurable brain cancer with a dismal prognosis. Median survival in unselected cohorts is less than 1 year (Ohgaki et al., 2004) . Current standard first line treatment of patients in good clinical condition involves tumour resection followed by radiochemotherapy with the alkylating drug temozolomide (Stupp et al., 2005) . After first line treatment tumour recurrence is imminent and the main reason for glioblastoma mortality. There is no established second line treatment for glioblastoma. Frequently nitrosoureas are used. Furthermore the VEGFA-targeting antibody bevacizumab that can cause local therapeutic hypoxia by decreasing vessel density is commonly used (Blagosklonny, 2004; Rapisarda et al., 2009; Weller et al., 2013; Fack et al., 2015; Scholz et al., 2015) .
The most commonly altered signalling cascade in glioblastoma is the receptor tyrosine kinase-Ras-PI 3 kinase-AKT signalling network with alterations found in close to 90% of tumours (Network TCGAR, 2008) . EGFR and PTEN are the major sources of genetic activation of this network and both are upstream regulators of mammalian target of rapamycin complex 1 (mTORC1) signalling. Thus, mTORC1 is a downstream component of the most commonly activated signalling cascade in glioblastomas. Additionally, lower grade gliomas, like diffuse (WHO II) and anaplastic (WHO III) gliomas have been shown to change their biological phenotype in the course of tumour recurrence and develop therapy resistance due to genetic mutations and clonal selection relying on activating mutations in the Akt-mTORC1 signalling pathway as a driver (Johnson et al., 2014) .
MTORC1 is a multiprotein complex and master regulator of cell growth, proliferation and metabolism. It receives signals from various stimuli including growth factor receptors (e.g. EGFR) as well as nutrient and oxygen availability (Laplante and Sabatini, 2012) . The main integrator of these signals is a heterotrimeric complex of the proteins hamartin and tuberin (TSC1 and TSC2) as well as the recently discovered TBC1D7 (Dibble et al., 2012) . This complex (termed TSC1/2 for simplicity) functions as a GTPase of the G-protein Ras homologue enriched in brain (RHEB), which in its GTP-bound state activates mTORC1 (Long et al., 2005) . TSC1/2 can be phosphorylated and inhibited by Akt mediating growth factor receptor signalling (Huang and Manning, 2008) . AMP-kinase, a major cellular energy sensor, can activate TSC1/2 by phosphorylation of a different residue (Huang and Manning, 2008) . Oxygen sensing involves the protein REDD1, which is HIF-1a-dependently transcribed and activates TSC1/2 (Brugarolas et al., 2004) . While TSC1/2 mutations are rare events in glioblastoma, these mutations are main genetic alterations in tuberous sclerosis complex, a genetic disease with multiple symptoms including development of subependymal giant cell astrocytomas (SEGAs) (Orlova and Crino, 2010) . Furthermore loss of the function of TSC1/2 can serve as a model for studying the effects of mTORC1 (hyper) activity. mTORC1 exerts its effects via various downstream targets. These involve the translational regulators ribosomal S6 kinase 1 (S6K1) and the S6K1 target S6 ribosomal protein (S6RP) where mTORC1-mediated phosphorylation activates S6K1 to phosphorylate its target S6RP as well as the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1, encoded by EIF4EBP1) where mTORC1-mediated phosphorylation relieves a translational block (Laplante and Sabatini, 2012) .
Due to its central role in key regulatory networks and frequent activation in glioblastoma, mTORC1 is considered a promising therapeutic target and clinical trials with inhibitors are in progress. However, we have previously shown that mTORC1 inhibition with rapamycin mediates hypoxia-protective effects by sustaining adenosine trisphosphate levels (Ronellenfitsch et al., 2009) . Therefore inhibition of upstream kinases such as EGFR (Steinbach et al., 2004) , Akt, and mTOR itself, could lead to adverse effects under the conditions of the tumour microenvironment by protecting hypoxic tumour cells. To assess the potential of mTORC1 as a therapeutic target, a deciphering of dependent effects is of paramount importance. To this end, we developed a model system with impaired TSC1/2 function. This model is wellsuited for mTORC1 signalling analysis since activation is induced proximally upstream of mTORC1, thereby limiting a potential interference of other signal transduction pathways. We report that TSC2 gene suppression sensitizes cells to hypoxia-induced cell death by inducing a metabolic programme involving components of the respiratory chain and pentose phosphate pathway. These results could help identify metabolically targetable tumours and pave the way to exploit this knowledge for future therapies.
Materials and methods

Reagents, cell lines and culture conditions
All reagents not specified were purchased from Sigma. LNT-229 and LN-308 cells were a kind gift of Dr N. de Tribolet (Lausanne, Switzerland) (Studer et al., 1985; Ronellenfitsch et al., 2009) , G55 cells were a kind gift of Manfred Westphal and Kathrin Lamszus (Hamburg) (Westphal et al., 1994) , LN-428 cells were a kind gift from Monika Hegi (Lausanne). Isocitrate dehydrogenase (IDH) mutation status was determined by sequencing for LNT-229 cells (Birner et al., 2014; Michel Mittelbronn personal communication) and by IDH1 R132H specific immunostaining of cell pellets in all other cell lines (data not shown). P53 and PTEN statuses have been reported previously (Ishii et al., 1999) , LNT-229 glioma cells differ by LN-229 cells only in having retained wild-type p53 status (Wischhusen et al., 2003) . The G55 cell line is p53 mutant (Kathrin Lamszus, personal communication). O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was determined by methylation-specific PCR. Key genetic features of the cell lines investigated in our study are summarized below (Table 1) .
Cell lines were maintained in Dulbecco's modified eagle medium (DMEM) containing 10% foetal calf serum (FCS) (Biochrom KG), 100 IU/ml penicillin and 100 mg/ml streptomycin (Life Technologies). pLKO.1 transfected cells were maintained in medium containing 2 mg/ml puromycin. When comparing different subcell lines, equal cell densities were confirmed by crystal violet staining in a parallel assay (Grady et al., 1960; Ronellenfitsch et al., 2009 ).
Generation of TSC2 gene suppressed cells
The pLKO.1 plasmids targeting TSC2 (TSC2sh) and the pLKO.1 plasmid with a non-targeting shRNA sequence (NTsh) were ordered from Addgene (Addgene #15478, #1864). Lentiviral production was performed according to the Addgene protocol in HEK293 cells using the packaging plasmid pCMV-dR8.2 dvpr (Addgene #8455) and envelope plasmid pCMV-VSVG (Addgene #8454). Lentiviral infection was carried out in the presence of polybrene (Millipore) using a multiplicity of infection of 3 (assuming one infectious unit for every 100 lentiviral particles according to the protocol of the p24-based assay, Takara/ Clontech,) yielding control (NTsh) and TSC2 gene suppressed (TSC2sh) cells. For selection 2 mg/ml puromycin (Sigma) was added to the culture medium, in the future passages 510% of cells detached as indication of not expressing the puromycin resistance cassette of the viruses and therefore undergoing cell death. We estimate an efficacy of transduction of $90% with our protocol for all cell lines used.
Induction of hypoxia
Hypoxia was induced as previously described (Ronellenfitsch et al., 2009; Wanka et al., 2012) . Briefly, 0.1% oxygen was induced by incubation in GasPak TM pouches for anaerobic culture (Becton-Dickinson) (Steinbach et al., 2003) . Cells were seeded and allowed to attach in DMEM containing 10% FCS overnight under normoxia. Subsequently, the medium was removed and the cells were incubated in serum-free DMEM adjusted to 2 mM glucose under normoxia or 0.1% oxygen for the indicated intervals.
RNA extraction and quantitative reverse transcription-PCR analysis
The quantitative PCR (qPCR) protocol used here has already been described (Wanka et al., 2012) . Briefly, for RNA purification TRIzol Õ and the RNeasy Õ Kit (Invitrogen) were used.
cDNA was synthesized with the Vilo cDNA synthesis kit (Invitrogen) (10 min at 25 C followed by 2 h at 42 C). Subsequently, the reaction was stopped at 85 C for 10 min. QPCR was performed in the IQ5 real-time PCR detection system (Bio-Rad) using ABsolute Blue 5'-CCCGCGTGGATCTCTAAGG -3', Rev: 5'-AATTTCTGGGCCAATACCATCTC-3', glucose-6-phosphate dehydrogenase (G6PD): Fwd: 5'-GGCAAGGCCCTG AACGA-3', Rev: 5'-CGGCCACATCATGGAACTG-3'. 18S and SDHA were both used as housekeeping genes for normalization. Cycle threshold (Ct) values were normalized for amplification of the 18S ribosomal RNA and the data were analysed using the Vandesompele method (Vandesompele et al., 2002) .
Immunoblot analysis
After the incubation period cells were washed with ice-cold PBS and immediately frozen by placing the dishes in fluid nitrogen. Lysates were prepared as described using lysis buffer P and subjected to SDS-PAGE analysis (Steinbach et al., 2003) . Membranes were probed with antibodies to TSC2, P-AKT (Ser 473), P-S6K1 (Thr 389), P-S6RP (Ser 240/244 and Ser 235/235), P-4E-BP1 (Ser 65), G6PD (Cell Signaling), EGFR or actin (Santa Cruz Biotechnology). The secondary anti-rabbit and anti-goat antibodies were purchased from Santa Cruz Biotechnology. Chemiluminescence solution was used for detection and was composed of 1 ml solution A (200 ml 0.1 M Tris-HCl pH 8.6, 50 mg luminol), 100 ml solution B (11 mg p-hydroxy coumaric acid, 10 ml DMSO) and 0.3 ml H 2 O 2 (30%). Quantification of immunoblot bands was performed by measuring the pixel density of scanned films using ImageJ software (NIH).
RHEB activation assay
The RHEB activation assay (NewEast Biosciences) was performed according to the manufacturer's protocol. Before RHEB-GTP immunoprecipitation the samples were adjusted to an equal protein concentration to ensure comparability and a portion of each sample was subjected to immunoblot analysis using actin as a loading control.
Cell density and cell viability assays
Cell density was assessed by crystal violet staining as previously described (Grady et al., 1960; Roth et al., 1997) . Cell viability measurement using propidium iodide (PI) uptake and flow cytometry has also been described (Ronellenfitsch et al., 2009) . Analysis was performed by flow cytometry using a BD Canto II flow cytometer and Summit 4.2. software. Cell viability analysis by a lactate dehydrogenase (LDH) release assay was performed with the Cytotoxicity Detection Kit (LDH) (Roche). The ATP assay (CLS II kit) was purchased from Roche. For ATP measurement, immediately after normoxic or hypoxic incubation the plates were placed on ice, the cells pelleted by centrifugation and lysed in ATP releasing reagent (Sigma). The ATP concentration was determined by a luciferase assay using MikroWin 2000 software and a Mithras luminometer (Ronellenfitsch et al., 2009) .
Reactive oxygen species analysis
Reactive oxygen species (ROS) analysis was performed as described previously (Wanka et al., 2012) . Cells were incubated in serum-free DMEM adjusted to 2 mM glucose under normoxia or 0.1% oxygen for the indicated intervals. Cells were then washed with PBS, incubated for 30 min, 37 C with 10 mM H 2 DCFDA (Invitrogen), washed with PBS and collected for flow cytometry analysis. The DCF signal was analysed by BD Canto II.
Measurement of glucose and lactate
Cell-free supernatant was collected and glucose and lactate concentrations were measured using the biochemistry analyser Hitachi 917.
Quantification of intracellular metabolites
Cells (500 000 per well) were seeded in a 6-well plate overnight and then incubated in serum-free DMEM adjusted to 2 mM glucose under normoxia or 0.1% oxygen for 8 h. The sampling approach and the processing of the samples were done as previously described (Hofmann et al., 2008) . Quantification of adenine nucleotides ATP, ADP and AMP was performed by LC-MS-MS analysis similar to a method described for thiopurine nucleotides (Hofmann et al., 2012) . Briefly, 50 ml of cell extract was added to a mixture of 250 ml of EDTA (50 mM, pH 10.5) and 10 ml of internal standard (100 pmol/ml each of 13 C-, 15 Nlabelled AMP and 13 C-labelled ATP/ADP). The mixture was heated at 95 C for 5 min and the samples subsequently were extracted by addition of 50 ml methanol followed by the addition of 250 ml dichloromethane with thorough mixing after each step. After centrifugation 5 ml of the supernatant was used for LC-MS-MS analysis. HPLC gradient elution was performed on a Biobasic AX column (2.1 Â 50 mm, 5 mm particle size, Thermo Fisher Scientific). Mobile phases A and B consisted of water: acetonitrile 7:3 (v/v), with 10 mM ammonium acetate at pH 6 for mobile phase A and with 1 mM ammonium acetate at pH 10.5 for mobile phase B. Ionization mode was electrospray (ESI), polarity positive. The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode using the following MRM transitions: 508 ! 136 for ATP, 518 ! 141 for . Intracellular concentrations of pyruvate, fumarate, malate, a-ketoglutarate and citrate were determined by GC-MS as described (Hofmann et al., 2008; Maier et al., 2009 ). Hexose-6-phosphate, phosphoenolpyruvate, fructose-1,6-bisphosphate, 6-phosphogluconate, sedoheptulose-7-phosphate, ribose-5-phosphate, and ribulose-5-phosphate were determined by LC-MS-MS similar to a described method (Maier et al., 2010) using (i) water:acetonitrile 87.5:12.5 (v/v); and (ii) water:acetonitrile 50:50 (v/v), each with 750 mg/l octylammonium acetate, as mobile phases.
Oxygen consumption
Cultured cells were overlaid with sterile paraffin oil. Oxygen consumption was measured with a fluorescence-based assay (PreSens).
High resolution respirometry
The steady state oxygen consumption of trypsinized NTsh and TSC2sh cells was determined by high resolution respirometry as described (Heide et al., 2012) . Briefly, 1.77-2.85 Â 10 6 (TSC2sh) and 2.05-2.8 Â 10 6 (NTsh) cells were resuspended per ml medium and transferred into the chambers of an Oxygraph-2 k (Oroboros). After recording the basal respiration at 37 C, 2 mM KCN were added to determine the mitochondria-independent oxygen consumption of the cells. Data were analysed with the corresponding DatLab5 software.
Statistical analysis
Quantitative data are expressed as indicated including standard deviation (SD). P-values were derived from two-tailed Student's t-tests. Values of P 4 0.05 were considered not significant (n.s.), values of P 5 0.05 and P 5 0.01 were considered significant and highly significant, respectively.
Results
TSC2 gene suppression activates mTORC1 signalling during nutrient deprivation and hypoxia
To investigate how tumour cells with defective nutrient sensing to mTORC1 respond to nutrient and oxygen deprivation, we chose TSC2 as a target for gene suppression to constitutively activate mTORC1. QPCR confirmed stable gene suppression of TSC2 in LNT-229 and LN-308 cells (TSC2sh) compared to control cells (NTsh) (Fig. 1A ). To confirm a functional relevance of TSC2 gene suppression, we measured mTORC1 activity in deprivation conditions. In medium containing 10% FCS without glucose restriction (25 mM glucose) no difference in the phosphorylation status of mTORC1 target proteins S6K1 and S6RP was detectable in normoxia (21% oxygen) (Fig. 1B) . In contrast, incubation of cells in medium with reduced glucose (2 mM glucose) alone or in combination with hypoxia (0.1% oxygen) revealed increased phosphorylation of S6K1 and S6RP in TSC2sh cells indicating defective suppression by deprivation (Fig. 1B) . This was also accompanied by increased levels of active (GTP-bound) RHEB in TSC2sh cells under deprivation conditions as a correlate of reduced TSC1/2-GTPase activity towards RHEB in these cells (Fig. 1B , lower two lanes). Total proteins were unaffected by the incubation conditions. A similar pattern of persisting phosphorylation of the mTORC1 target 4E-BP1 was observed in TSC2sh cells, while the mobility shift towards faster migrating hypophosphorylated bands of 4E-BP1 was less pronounced in both LNT-229 and LN-308 TSC2sh cells in accordance with previously published results (Fig. 1B) (Gingras et al., 2001; Ronellenfitsch et al., 2009) . Similar results were obtained with G55 and LN-428 glioma cells (Fig. 1C and D) . Notably, in PTEN-mutated LN-308 NTsh as well as G55 NTsh cells, a stronger persistence of mTORC1-dependent phosphorylation signals was detectable than in PTEN wildtype LNT-229 and LN-428 cells (Fig. 1B and D) . TSC2 gene suppression led to an almost unchanged and persisting phosphorylation of S6RP and 4E-BP1 under deprivation conditions in LN-308 and G55 cells (Fig. 1B and D) , whereas in LNT-229 and LN-428 TSC2sh cells, a decrease in the phosphorylation of S6RP and 4E-BP1, although to a lesser degree than in the NTsh control cells, was still detectable (Fig. 1B  and D) . Since different rates of proliferation may influence the sensitivity to starvation of TSC2sh cells, we performed growth analyses in serum-free and serum containing (10% FCS) culture conditions without glucose restriction (25 mM glucose). TSC2 gene suppression had no effect on cell density in both glioma cell lines (Fig. 1E) in accordance with the similar degree of mTORC1 activation observed in NTsh and TSC2sh cells in the immunoblots in nutrient-rich conditions (Fig. 1B) .
TSC2 gene suppression sensitizes human malignant glioma cells to hypoxia-induced cell death
We have previously shown that mTORC1 inhibition protects glioma cells from hypoxia-induced cell death (Ronellenfitsch et al., 2009) . To test whether deregulated and enhanced mTORC1 signalling (conversely) decreases survival in glucose-and oxygen-restricted conditions, we performed cell viability measurements. LNT-229 and LN-308 TSC2sh cells displayed enhanced sensitivity to hypoxia-induced cell death as indicated by an increased LDH release as well as propidium iodide uptake ( Fig. 2A) . Similar results were obtained with G55 and LN-428 glioma cells (Fig. 2B) . Quantification of cellular ATP content confirmed that this effect was associated with preceding ATP depletion in TSC2sh cells (Fig. 2C) . Furthermore, the production of reactive oxygen species as a measure of cellular stress was increased in TSC2sh cells in deprivation conditions (Fig. 2D ).
TSC2 gene suppression alters metabolic pathways
We have recently shown that rapamycin or mTOR gene suppression-mediated mTORC1 inhibition had no effect on glucose consumption (Ronellenfitsch et al., 2009) . In line with these results, TSC2sh cells displayed similar glucose consumption and lactate production as the corresponding NTsh control cells (Fig. 3A) . Using a metabolome analysis we further mapped alterations in TSC2sh cells to distinct pathways. Energy charge, ATP and adenosine phosphates were reduced in TSC2 gene-suppressed LNT-229 cells (Fig. 3B) . With regard to glycolytic metabolites, hexose-6-phosphate was reduced in hypoxia in LNT-229 TSC2sh cells, while NTsh cells and normoxic TSC2sh cells had similar levels (Fig. 3B) . Normoxic levels of fructose-1, 6-bisphosphate (fructose-1, 6 BP) were comparable and hypoxia caused a similar decline in both LNT-229 TSC2sh and NTsh cells (Fig. 3B ). This decline was more pronounced in TSC2sh cells for the metabolite phosphoenolpyruvate (Fig. 3B) . Pyruvate levels were comparable in the tested conditions (Fig. 3B) . With regard to metabolites of the pentose phosphate pathway, 6-phosphogluconate (6PG) was reduced in LNT-229 TSC2sh cells. Hypoxia caused a further decline in 6PG levels, rendering 6PG almost undetectable in LNT-229 TSC2sh cells in hypoxia. Sedoheptulose-7-phosphate (Sed-7P) was increased in LNT-229 TSC2sh cells and hypoxia caused a decline in both NTsh and TSC2sh cells (Fig. 3B) . In contrast both ribose-5-phosphate (Ribo-5P) and ribulose-5-phosphate (Ribu-5P) were not affected by hypoxia. Ribo-5P was increased in LNT-229 TSC2sh cells (Fig. 3B) . With regard to the citric acid cycle, fumarate and citrate were unaffected by hypoxia in LNT-229 cells. No difference in fumarate between NTsh and TSC2sh cells was detectable (Fig. 3B) . Malate was only reduced in hypoxia in TSC2sh cells (Fig. 3B) . Intracellular citrate levels were also comparable between TSC2sh and NTsh cells (Fig. 3B) . A similar pattern with reduction of hexose-6-phosphate in hypoxia as well as accumulation of Sed-7P regardless of oxygenation was observed in LN-308 TSC2sh cells (Supplementary Fig.  1 ). With regard to the citric acid cycle, LN-308 TSC2sh cells had increased levels of citrate and malate in normoxia, Figure 2 TSC2 gene suppression sensitizes human malignant glioma cells to hypoxia-induced cell death. Cells were exposed to glucose restricted (2 mM glucose) serum-free DMEM under normoxic conditions or 0.1% oxygen until cell death (24 h), ATP depletion (12 h) or an increase in ROS (8 h) was observed. (A) Cell death was quantified by LDH release and by propidium iodide staining (n = 4, mean AE SD, * P 5 0.05, ** P 5 0.01). (B) G55 and LN-428 NTsh and TSC2sh cells were exposed to glucose restricted (2 mM glucose) serum-free DMEM under normoxic conditions or 0.1% oxygen until cell death (24 h) was observed. Cell death was quantified by LDH release (n = 4, mean AE SD, * P 5 0.05, ** P 5 0.01). (C) ATP was quantified by a luciferase-based assay. The ratio of ATP concentrations in hypoxia to normoxia is depicted (n = 5, mean AE SD, ** P 5 0.01). (D) ROS levels were measured by H 2 DCFDA-FACS (n = 3, mean AE SD, * P 5 0.05, ** P 5 0.01). n.s. = not significant; ROS = reactive oxygen species.
Figure 3 TSC2sh gene suppression has no effect on glucose consumption and lactate production, but alters metabolic pathways. (A) Cells were exposed to glucose restricted (2 mM glucose) serum-free DMEM under normoxic conditions or 0.1% oxygen for 8 h. Glucose consumption and lactate production were determined in the supernatant (n = 3, mean AE SD). (B) Cells were exposed to glucose restricted (2 mM glucose) serum-free DMEM under normoxic conditions or 0.1% oxygen for 8 h. Intracellular metabolites were analysed either by LC-MS-MS analysis or GC-MS analysis (n = 3, mean AE SD, * P 5 0.05, ** P 5 0.01). (C) LNT-229 and LN-308 NTsh and TSC2sh cells were exposed to glucose restricted (2 mM glucose) serum-free DMEM under normoxic conditions or 0.1% oxygen for 4 h, cDNA and cellular lysates of cells were generated. Gene expression of G6PD was quantified by qPCR, values are normalized to 18S as well as SDHA housekeeping gene expression (n = 3, mean AE SD, * P 5 0.05) (left). Cellular lysates were analysed by immunoblot with antibodies for G6PD or actin. Quantification of G6PD protein content of three independent experiments is provided (n = 3, mean AE SD, * P 5 0.05, ** P 5 0.01) and one representative immunoblot is shown (middle). LNT-229 and LN-308 wild-type cells were exposed to medium containing 10% FCS with 25 mM glucose with 200 nM rapamycin, 200 nM torin2 or vehicle for 72 h. Cellular lysates were analysed by immunoblot with antibodies for G6PD, P-S6RP (Ser 240/244 and Ser 235/235), S6RP, P-4E-BP1 (Ser 65), 4E-BP1 or actin. n.s. = not significant.
which was not observed in LNT-229 TSC2sh cells ( Supplementary Fig. 1 ). Taken together, with regard to glycolysis, a difference of the metabolite hexose-6-phosphate was observed with lower levels in LNT-229 as well as LN-308 TSC2sh cells compared to NTsh cells in hypoxia. Furthermore, metabolites of the pentose phosphate pathway (Sed-7P and Ribo-5P) did accumulate ( Supplementary Fig. 2) . As hexose-6-phosphate is the metabolite that can be processed in glycolysis as well as the pentose phosphate pathway (Eggleston and Krebs, 1974) , we hypothesized that TSC2sh cells upregulate pentose phosphate pathway flux. It has already been shown in mouse embryonic fibroblasts that mTORC1 activates the pentose phosphate pathway by transcriptional activation of G6PD, which catalyses the first and rate limiting step (Duvel et al., 2010) . Therefore we investigated the mRNA and protein levels of G6PD in LNT-229 and LN-308 NTsh and TSC2sh cells. Under glucose-restricted, normoxic conditions, mRNA levels of G6PD did not differ between NTsh and TSC2sh cells. In hypoxia, TSC2sh cells had increased mRNA levels of G6PD (Fig. 3C, left) . A similar effect was detectable after a prolonged exposure to glucose restriction and normoxia or hypoxia (Supplementary Fig. 3A ). G6PD protein was increased in normoxia and hypoxia in TSC2sh cells ( Fig. 3C and Supplementary Fig. 3A ). Under high glucose, serum-containing conditions, mRNA levels of G6PD did not differ between NTsh and TSC2sh cells and an increase in protein levels of G6PD was only observed in LNT-229 TSC2sh cells ( Supplementary Fig. 3B ), a result that could indicate additional modes of regulation depending on the genetic background of cells and environmental/culture conditions. Notably no difference in protein expression was also detected in LN-428 cells in contrast to G55 cells ( Supplementary Fig. 3C ). Treatment with the first generation mTORC1 inhibitor rapamycin or the ATP-competitive and more potent mTORC1 and 2 inhibitor torin2 resulted in different levels of mTORC1 inhibition as indicated by different levels of phosphorylation of the mTORC1 target 4E-BP1 (Liu et al., 2011) . Accordingly, torin2 considerably reduced G6PD levels whereas rapamycin had only a slight effect (Fig. 3C) . A reduced level of G6PD protein in cells treated with torin2 was also detectable under glucose-restricted conditions in hypoxia ( Supplementary Fig. 3D ).
TSC2 gene suppression induces oxygen consumption and expression of genes of mitochondrial oxidative function
An increase in oxygen consumption has previously been reported in TSC2 knockout mouse fibroblasts (Cunningham et al., 2007) . LNT-229 TSC2sh cells similarly displayed an increase in oxygen consumption as indicated by reduced oxygen concentration in the culture medium (Fig. 4A) . Analysis of mitochondrial functionality by high resolution respirometry also revealed an increase in steady state oxygen consumption in LNT-229 TSC2sh cells (Fig. 4A) . In LN-308 TSC2sh cells, no significant difference in oxygen consumption was observed compared to NTsh cells (data not shown). This might be explained by the weaker gene suppression efficacy (Fig. 1A) . In G55 and LN-428 TSC2sh cells an increase in oxygen consumption was detected similar to LNT-229 cells ( Supplementary Fig. 4A and B) . mTORC1 signalling activates mitochondrial oxidative function by inducing a transcriptional programme involving transcription of peroxisome proliferator-activated receptor gamma coactivator (PGC)-1a (encoded by PPARGC1A) (Cunningham et al., 2007) . Genes with increased transcription in TSC2 knockout mouse fibroblasts besides Ppargc1a/ PGC-1a included the mitochondrial transcriptional regulators Ppargc1b/PGC-1b, oestrogenic-related receptor-a (Esrra/ERR-a) and nuclear respiratory factor 1 (Nrf1) as well as other mitochondrial genes (Cunningham et al., 2007) . To test if this was also true for human malignant glioma cells, we quantified gene expression of (A) LNT-229 NTsh and TSC2sh cells were incubated in medium containing 10% FCS with 25 mM glucose. Oxygen consumption was measured by a fluorescence-based assay (left, n = 3, mean, ** P 5 0.01). Using an Oxygraph-2k system steady state oxygen consumption was also monitored (right, n = 5 mean + SD, ** P 5 0.01). (B) cDNA of LNT-229 and LN-308 NTsh and TSC2sh cells cultured in standard conditions was generated. Gene expression of PPARGC1A/PGC-1a and PPARGC1B/PGC-1b, ERRSA/ERR-a, NRF1, MT-CYB, MT-CO1, MT-CO2, SCO2, ATP5G1, COX5A and IDH3A was quantified by qPCR, values are normalized to 18S as well as SDHA housekeeping gene expression (n = 3, mean AE SD, * P 5 0.05, ** P 5 0.01). n.s. = not significant. mitochondrial transcription factors and mitochondrial genes by qPCR: expression of PPARGC1A/PGC-1a and PPARGC1B/PGC-1b, MT-CYB, MT-CO1 and SCO2 were induced in both LNT-229 and LN-308 cells following TSC2 gene suppression (Fig. 4B) . ERR-a, MT-CO2 and Atp5g1 were only induced in LN-308 TSC2sh cells (Fig.  4B) . NRF1, COX5a and IDH3a were not significantly altered following TSC2 gene suppression (Fig. 4B ). G55 and LN-428 cells displayed a similar increase in PPARGC1A/PGC1a and ESRRA/ERR-a gene expression, whereas PPARGC1B/PGC-1b was not increased (Supplementary Fig. 4C ).
Inhibition of mTORC1 reduces oxygen consumption and expression of mitochondrial oxidative function genes
Vice versa, mTORC1 inhibition with rapamycin reduced oxygen consumption in LNT-229 and LN-308 wild-type cells, as indicated by higher oxygen content in the culture medium (Fig. 5A ). In addition levels of PPARGC1A/PGC1a, PPARGC1B/PGC-1b, ESRRA/ERR-a, SCO2 and ATP5G1 were reduced after mTORC1 inhibition with rapamycin in LN-308 wild-type cells (Fig. 5B) . In LNT-229 wild-type cells only expression of PPARGC1B/PGC1b and ESRRA/ERR-a was reduced (Fig. 5B) .
Inhibition of mTORC1 reverses the phenotype of TSC2sh cells
Pharmacological mTORC1 inhibition with rapamycin in LNT-229 TSC2sh cells reversed the phenotype as indicated by similar oxygen consumption in comparison to vehicletreated NTsh cells (Fig. 6A ). This effect was accompanied by a reduced expression of PPARGC1A/PCG-1a and PPARGC1B/PGC-1b mRNA in TSC2sh cells treated with rapamycin (Fig. 6B) .
Discussion mTORC1 is activated in human glioblastomas by the most commonly altered signalling cascades. Its central relevance as a major controller of cell growth, metabolism and proliferation has widely been acknowledged and effective mTORC1-targeted therapies have been successfully used in treatment regimens for cancer, including breast and renal tumours (Hudes et al., 2007; Baselga et al., 2012) . Due to its central role and frequent activation, mTORC1 is also under investigation to better treat glioblastomas.
In our study, we investigated specific effects of activated mTORC1 signalling. We included energy-limiting conditions as can be found in the tumour microenvironment to better understand the spectrum of mTORC1-mediated effects and also because we have previously shown that tumour cells can adapt and survive by downregulation of the mTORC1-dependent signalling cascade when energy becomes limited (Ronellenfitsch et al., 2009; Kim et al., 2013) . In this context, we found that pharmacological inhibition of EGFR and mTORC1 triggers metabolic changes leading to adverse effects by protecting hypoxic tumour areas from hypoxia-induced cell death (Steinbach et al., 2003; Ronellenfitsch et al., 2009) . Therefore metabolically-triggered adaptive mTORC1 inhibition is also one possible mechanism of intrinsic resistance to starvation-inducing therapies and can be enhanced by pharmacological inhibition of EGFR and mTORC1 signalling. Using a panel of glioma cells to account for genetic heterogeneity, we here show conversely that activated mTORC1 signalling renders tumour cells more vulnerable to hypoxia-induced cell death. This effect was accompanied by an earlier ATP depletion and an increase in reactive oxygen species. There was no difference in extracellular glucose consumption but we detected an altered intracellular metabolic profile with an increase of pentose phosphate pathway intermediates. Mechanistically, mTORC1 activated the pentose phosphate pathway by upregulation of its first and rate limiting enzyme G6PD in a transcriptional and post-transcriptional manner depending on the culture conditions. These results are in accordance with previously published results in mouse embryonic fibroblasts that showed a transcriptional regulation of G6PD (Duvel et al., 2010) . Notably, a regulation of G6PD was found in all investigated cell lines but LN-428 ( Supplementary Fig. 3C ), which indicates additional modes of regulation in some glioblastoma cells. The steroid dehydroepiandrosterone (DHEA) has been shown to inhibit G6PD activity in breast cancer cells (Di Monaco et al., 1997) . It is interesting to note that DHEA treatment led to a protection from hypoxia-induced cell death in LNT-229 TSC2sh cells, which might indicate a potential contribution of G6PD to the observed phenotype ( Supplementary Fig. 5 ). Furthermore, an increase in oxygen consumption in TSC2sh cells was observed. In line with these results mTOR inhibition with rapamycin reduced oxygen consumption and the increased oxygen consumption rate of TSC2sh cells was abolished after treatment with rapamycin. mTORC1 transcriptionally regulated genes involved in mitochondrial respiratory function including the transcription factors PPARGC1A/PGC-1a and PPAR GC1B/PGC-1b, ESRRA/ERR-a as well as other respiratory chain associated genes offering one plausible explanation for the differences in oxygen consumption. Notably, we used 0.1% oxygen for the hypoxia experiments. Such low oxygen concentrations can be found in solid tumours and are necessary to reveal the full spectrum of hypoxic effects, including e.g. effects on cellular oxygen consumption in some settings (Hockel and Vaupel, 2001) .
TSC mutations are main genetic alterations in SEGAs that can frequently be found in patients with tuberous sclerosis (Orlova and Crino, 2010) . In contrast to malignant gliomas/glioblastomas (WHO IV), SEGAs are rather benign (WHO I) with slower growth rates. Necrosis is not observed in SEGAs. In a pilot experiment, no HIF-1a was detectable in a SEGA, suggesting no relevant oxygen deprivation in these tumours while mTORC1 signalling is active as evidenced by detection of P-S6RP in the tissue ( Supplementary Fig. 6 ). Therefore in this tumour entity, mTOR-inhibitor therapy-mediated resistance to hypoxia is not expected to be relevant and so far, intriguingly, has also not been reported (Krueger et al., 2010) . In glioblastomas, TSC1 and TSC2 mutations with a frequency of 0.5% and 0.6%, respectively, are rare events (Forbes et al., 2015) . However, the most common genetic alterations in glioblastoma converge at mTORC1 and phosphorylation of mTORC1 downstream targets is a marker of mTORC1 activity rather than being suggestive for a single mutation. For example, $20% of glioblastomas display an activating mutation in the EGFR that leads to a lower molecular weight protein with constitutive ligand-independent signalling termed EGFR vIII (Weller et al., 2014) . While expression of EGFR-mutated proteins is frequently lost when glioma cells are cultured in the laboratory (Liffers et al., 2015) , PTEN mutant cell lines are available. In an exploratory approach, LNT-229 cells engineered to express EGFR vIII displayed increased mTORC1 signalling under deprivation conditions and were more sensitive to hypoxia-induced cell death in comparison to LNT-229 cells overexpressing wild-type EGFR (EGFR wt) or a kinase-deficient EGFR vIII variant (EGFR dk) ( Supplementary Fig. 7 ). Mutations of PTEN or other proteins involved in signal transduction upstream of mTORC1 are plausible reasons for differences in basal signalling activity that might become apparent especially under deprivation conditions. In this respect, LN-308 (PTEN mutant) and G55 cells (PTEN status unknown) displayed a stronger persistence of mTORC1-dependent phosphorylation signals than LNT-229 or LN-428 cells (both PTEN wild-type) (Fig. 1B and D) . These effects were detectable to some degree both in NTsh and TSC2sh cells. Our model of TSC2 gene suppression-mediated mTORC1 activation limits inclusion of other upstream signalling branches, thereby allowing characterization of mainly mTORC1-mediated effects. It is important to note that recently TSC-dependent and mTORC1-independent effects have been reported (Alves et al., 2015) . With regard to our experiments, however, the sensitivity of the effects, e.g. oxygen consumption, to mTOR inhibitors indicate the canonical TSC1/2 signalling cascade to mTORC1 as the (most) relevant central axis in this context. Additionally in our previous study we could show that vice versa, mTOR inhibition protected glioma cells from hypoxiainduced cell death (Ronellenfitsch et al., 2009) . However, some contribution of TSC-dependent and mTORC1-independent effects cannot definitely be ruled out. In light of some first negative clinical trials with direct or indirect mTORC1 inhibitors in glioblastoma, ), a precise deciphering of mTORC1-mediated effects in glioblastoma is necessary not only for a further evaluation of mTORC1 inhibitors in glioblastoma, but also to identify tumours where mTORC1 activation might expose a (metabolically) targetable Achilles' heel. In translation of our findings to the tumour biology and histology of glioblastoma, we propose a model where tumours with deregulated mTORC1 signalling are defective in adaptive responses to deprivation/starvation conditions and more vulnerable to cell death (Fig. 7) . Furthermore, after initial chemotherapy activating mutations in the Akt-mTORC1 signalling pathway have been shown to arise in gliomas (Johnson et al., 2014) . At tumour recurrence bevacizumab is commonly administered in glioblastoma patients. Many preclinical and clinical studies have shown that bevacizumab induces an increase in the expression of hypoxia inducible factor-1a (HIF-1a) or its target genes (de Groot et al., 2010; Rieger et al., 2010; Keunen et al., 2011; DeLay et al., 2012; Hu et al., 2012; Bahr et al., 2014; Fack et al., 2015) . So far, some subgroups of glioblastoma patients with different sensitivities to bevacizumab have been described (Sandmann et al., 2015) . However, there is no widely available and cost-effective biomarker that can predict response to bevacizumab treatment (or other potential hypoxia-inducing therapies). Based on our results, activation of mTORC1-dependent signalling, e.g. evaluated in routine formalin-fixed brain tumour specimens , could possibly represent a predictive marker for response to hypoxia-inducing therapies including treatment with bevacizumab by counteracting adaptive alterations of tumour metabolism. Oxygen concentration as well as nutrient availability decline with increasing distance from blood vessels. When the oxygen concentration falls below a threshold, HIF-1a is induced. Depending on the quality of their sensor, cells inhibit mTORC1 signalling via TSC1/2 activation for adaptation. When cellular sensors are deregulated, e.g. in TSC2sh cells, starvation-and hypoxia-induced cell death is more widespread. Other indirect mTORC1 activating mutations like mutated EGFR (e.g. EGFR vIII mutation) and loss of PTEN might add to a deregulated mTORC1 sensor in glioblastomas.
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